MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Denali Therapeutics Net Income 2011-2025 | DNLI
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Denali Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -423 M | -145 M | -326 M | -291 M | 71.1 M | -198 M | -36.2 M | -88.2 M | -86.7 M | -16.8 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.1 M | -423 M | -154 M |
Quarterly Net Income Denali Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -127 M | -124 M | -133 M | - | -107 M | -99 M | -102 M | - | -99.4 M | 183 M | -110 M | - | -103 M | -58.8 M | -65.2 M | - | -84.6 M | -60.7 M | -70 M | - | -58.2 M | -58.8 M | -56.8 M | -54 M | -46.3 M | -58.3 M | -39 M | 77.5 M | -35.4 M | -54.7 M | -23.7 M | -22.9 M | -21.8 M | -22.1 M | -21.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 183 M | -133 M | -55.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-72.8 M | $ 4.77 | 1.27 % | $ 792 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-132 M | $ 3.33 | 2.61 % | $ 257 M |  USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
-4.27 M | $ 1.31 | 0.85 % | $ 7.14 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 218.02 | -1.09 % | $ 5 B |  Danmark |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.2 | -2.74 % | $ 7.7 B |  Australia |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
-17.5 M | $ 1.43 | -1.7 % | $ 2.11 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
BioNTech SE
BNTX
|
10.3 B | $ 94.46 | -0.37 % | $ 27.2 B | Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
-114 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Aeglea BioTherapeutics
AGLE
|
-208 M | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-8.63 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
160 M | $ 25.93 | 2.61 % | $ 1.26 B | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-82.7 M | $ 9.58 | 0.21 % | $ 140 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.88 M | $ 0.28 | -1.82 % | $ 609 M |  Israel |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |
 |
Catalyst Biosciences
CBIO
|
-85.5 M | $ 14.27 | 1.28 % | $ 939 M | USA |
 |
Athersys
ATHX
|
-87 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
377 M | $ 563.27 | -0.18 % | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.33 | 1.3 % | $ 14.6 M | USA |
 |
AstraZeneca PLC
AZN
|
115 M | $ 90.67 | 0.94 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 8.95 | -0.61 % | $ 1.46 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
-645 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-847 M | $ 11.68 | 1.26 % | $ 755 M | USA |
 |
Biogen
BIIB
|
1.63 B | $ 171.54 | -1.47 % | $ 25 B | USA |
 |
Abeona Therapeutics
ABEO
|
-54.2 M | $ 5.34 | -0.37 % | $ 114 M | USA |
 |
ADiTx Therapeutics
ADTX
|
-40.4 M | $ 2.11 | -5.61 % | $ 27.8 K | USA |
 |
Cellectar Biosciences
CLRB
|
-42.8 M | $ 3.6 | -0.55 % | $ 44 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-25 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-98 M | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Завод ДИОД
DIOD
|
37.2 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-525 M | - | - | - | Russia |
 |
BioLineRx Ltd.
BLRX
|
-27.1 M | $ 3.33 | 0.91 % | $ 908 M | Israel |